Related Experiment Videos
[Effectiveness and tolerance of genetically engineered vaccines for hepatitis B--a comparative study]
1Institut für Arbeits- und Sozialmedizin, Universität Erlangen-Nürnberg.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|May 1, 1992
Summary
Two gene technology hepatitis B vaccines were compared in German nurses. Both showed high efficacy and tolerance, but one with 20 micrograms HBs antigen yielded 1.8 times higher antibody titers.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Hepatitis B virus (HBV) infection poses a significant risk to healthcare professionals.
- Gene technology has produced advanced vaccines for HBV prevention.
- Assessing the comparative performance of available vaccines is crucial for optimizing public health strategies.
Purpose of the Study:
- To compare the efficacy and tolerance of two available gene technology-derived hepatitis B vaccines.
- To evaluate the immunogenicity, specifically anti-HBs antibody titers, induced by each vaccine.
- To provide updated recommendations for hepatitis B vaccination in at-risk populations.
Main Methods:
- A comparative study involving 80 nurses undergoing training in Germany.
- Administration and monitoring of two distinct gene technology hepatitis B vaccines.
- Measurement of anti-HBs antibody titers to assess immunogenic response.
Main Results:
- Both hepatitis B vaccines demonstrated high efficacy and excellent tolerance in the study population.
- A significant difference in achieved anti-HBs antibody titers was observed between the two vaccines.
- Vaccine utilizing 20 micrograms of HBs antigen resulted in antibody titers 1.8 times higher than the comparator.
Conclusions:
- Gene technology hepatitis B vaccines are effective and well-tolerated preventive measures.
- Vaccine composition, specifically HBs antigen content, influences immunogenicity.
- Updated vaccination strategies may be warranted for risk groups based on comparative vaccine performance.